Recce Pharmaceuticals Ltd RECEF
0.22 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
0.60 Day range 0.60
0.22 52-week range 0.60
- YTD
- 0.00%
- 1 year
- 0.00%
News
proactiveinvestors.com Recce Pharmaceuticals signs Arrotex deal for RECCE 327 in Australia and New Zealand Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has signed an exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals for RECCE® 327 topical gel in Australia and New Zealand,…
proactiveinvestors.com Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has reached a key milestone in its pivotal Phase 3 diabetic foot infection trial, with an independent Data Monitoring Committee (DMC) set to review…
proactiveinvestors.com Snowflake shares surge after Q2 beat, raised guidance Snowflake Inc (NYSE:SNOW) shares jumped 23% in after-hours trading Wednesday after the cloud data company posted second-quarter results that beat Wall...
proactiveinvestors.com Polymarket valuation hits $21bn as Trump Jr's firm leads $1bn round Polymarket, the blockchain-based prediction-market platform, is raising $1 billion in a new funding round that values the company at $21 billion on a...
proactiveinvestors.com Baidu misses Q2 revenue and earnings estimates as core business slips Baidu.com (NASDAQ:BIDU) shares fell 9.3% in Tuesday morning trading after the Chinese tech giant reported second-quarter results that missed analyst...
proactiveinvestors.com Bank of England holds rates but three dissenters vote for hike The Bank of England held interest rates at 3.75% but three policymakers voted for an increase as renewed tensions in the Middle East raised the risk of...
proactiveinvestors.com Recce Pharmaceuticals positioned for US$66.9 billion US biodefence strategy Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is positioned to benefit from a new five-year, US$66.9 billion US Government strategy aimed at strengthening...
proactiveinvestors.com Recce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarter Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) advanced its diabetic foot infection treatment toward commercialisation during the June quarter, securing...
proactiveinvestors.com Twilio faces higher bar heading into quarterly earnings, says Jefferies Twilio Inc (NYSE:TWLO) is expected to deliver second quarter results that exceed expectations on revenue and operating income, with investors likely to...
proactiveinvestors.com Halliburton tops Q2 earnings estimates as CEO warns of softer oilfield services market Halliburton Company (NYSE:HAL, XETRA:HAL) reported second quarter results that exceeded Wall Street expectations, but shares fell more than 6% after...
proactiveinvestors.com Recce Pharmaceuticals extends share purchase plan deadline to July 24 Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has extended the closing date of its share purchase plan (SPP) to 5:00pm AEST on Friday, July 24, giving...
proactiveinvestors.com Recce patent extends Vietnam protection to 2041 - ICYMI Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) earlier this week strengthened its intellectual property position in Southeast Asia after securing a...
proactiveinvestors.com Amazon seen well-positioned going into Q2 report on AWS momentum, Prime Day spending Amazon.com Inc (NASDAQ:AMZN) is well-positioned heading into its second-quarter earnings report, according to Jefferies, which reiterated the e-commerce and...
proactiveinvestors.com Dow dips but Nasdaq higher after soft CPI and good bank earnings offset IBM shocker 12:00pm: 'Benign' inflation print LPL Financial chief economist Jeffrey Roach said June's cooler-than-expected inflation report was largely driven by a...
proactiveinvestors.com Crypto's landmark Clarity Act stalls in Senate as passage odds sink to 39% Prediction market traders now put the chances of the Clarity Act becoming law this year at just 39%, down sharply from a peak above 80% in February. The...
proactiveinvestors.com Small Cap Watch: biotech, gold and critical minerals explorers deliver key milestones The S&P/ASX Small Ordinaries Index (ASX:XSO) slipped 25.1 points, or 0.74%, to 3,367.6, extending its five-day decline to 1.68% as weakness across the...
proactiveinvestors.com Recce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestones Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has strengthened its balance sheet with the receipt of a A$3.67 million income tax refund from the Australian...
proactiveinvestors.com Panmure Liberum says wine takeover exposes deep value at Naked and Virgin Panmure Liberum has argued that a take-private bid for Sweden's Viva Wine Group lays bare how cheaply the UK's direct-to-consumer wine companies are...
proactiveinvestors.com Recce raises A$4M as it advances anti-infective trials and commercial licensing plans; another $4M to come in SPP Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has raised A$4 million to support commercial licensing activity, clinical trials and regulatory-enabling work...
proactiveinvestors.com Nasdaq set to take another hit from rotation out of tech before quarter-end US stocks are set for another difficult session on Friday, with the Nasdaq on course for a fifth straight day of losses as investors continue to rotate out...